CLDN18 and neoplasm: In the MONO trial moderate or strong (2+/3+) CLDN18 membrane staining intensity in 50% of tumor cells was reported in 54/120 patients (45%) and higher expression levels (2+/3+ in 70% of tumor cells) appeared in 29/120 (24%) of patients [38].